Adaptimmune Therapeutics PLC’s (ADAP) “Outperform” Rating Reiterated at Leerink Swann
Adaptimmune Therapeutics PLC (NASDAQ:ADAP)‘s stock had its “outperform” rating reiterated by investment analysts at Leerink Swann in a research report issued to clients and investors on Friday. They currently have a $15.00 price objective on the biotechnology company’s stock. Leerink Swann’s price target suggests a potential upside of 67.97% from the stock’s current price.
A number of other equities analysts have also recently weighed in on the company. BidaskClub raised Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Zacks Investment Research cut Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $12.08.
Adaptimmune Therapeutics PLC (NASDAQ ADAP) traded up 18.28% during trading on Friday, reaching $8.93. The company’s stock had a trading volume of 1,710,060 shares. The stock has a 50-day moving average of $5.62 and a 200 day moving average of $5.16. The firm’s market capitalization is $835.12 million. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $8.95.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.24). The company had revenue of $3.52 million during the quarter, compared to analysts’ expectations of $5.43 million. Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. On average, equities research analysts predict that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Adaptimmune Therapeutics PLC’s (ADAP) “Outperform” Rating Reiterated at Leerink Swann” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/08/adaptimmune-therapeutics-plcs-adap-outperform-rating-reiterated-at-leerink-swann.html.
Several institutional investors have recently made changes to their positions in ADAP. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at approximately $120,000. KCG Holdings Inc. acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at approximately $133,000. Monashee Investment Management LLC acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at approximately $138,000. OxFORD Asset Management LLP acquired a new position in shares of Adaptimmune Therapeutics PLC during the second quarter valued at approximately $156,000. Finally, Paloma Partners Management Co acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at approximately $165,000. 68.01% of the stock is owned by institutional investors and hedge funds.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.